Article Text

PDF
Intravenous thrombolysis for ischaemic stroke: short delays and high community-based treatment rates after organisational changes in a previously inexperienced centre
  1. A Tveiten1,
  2. Å Mygland1,3,4,
  3. U Ljøstad1,
  4. L Thomassen2
  1. 1
    Department of Neurology, Sørlandet Hospital Kristiansand, Norway
  2. 2
    Department of Neurology, Haukeland University Hospital, Bergen, Norway
  3. 3
    Institute of Clinical Medicine, University of Bergen, Bergen, Norway
  4. 4
    Hospital of Rehabilitation, Rikshospitalet University Hospital, Kristiansand, Norway
  1. Dr A Tveiten, Department of Neurology, Sorlandet Sykehus Kristiansand, 4604 Kristiansand, Norway; arnstein.tveiten{at}sshf.no

Abstract

Aim: To evaluate hospital delays in thrombolytic treatment before and after organisational changes and community-based treatment rates in a previously inexperienced centre.

Methods: The delays before and after organisational changes made in 2006 were compared using a prospective treatment database. In a 6-month period in 2007, a community-based search was performed for all hospitalisations for ischaemic stroke. The number of patients admitted within the 0–3 h time window and the proportion treated with tissue plasminogen activator were analysed.

Results: The number of treatments increased fourfold from 2005 to 2007 with a significant reduction in mean door-to-needle time from 60 min to 38 min (p = 0.002). In the community-based series, 14/137 patients (10%) hospitalised with ischaemic stroke and 13/32 patients (41%) admitted in the 0–3 h window were treated.

Conclusions: An inexperienced stroke centre can rapidly implement the necessary logistics to deliver thrombolysis to a large proportion of patients with acute stroke with short hospital delays. Important factors are probably prenotification of a team and the initiation of thrombolytic treatment in the emergency room.

Statistics from Altmetric.com

Footnotes

  • Competing interests: AT and LT have received travel grants and honoraria from Boehringer Ingelheim GmbH.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Primary survey
    Jonathan Wyatt